Abstract：
OBJECTIVE: This study aimed to investigate the association of bisphosphonates with outcomes related to radiographic changes and pain in hip osteoarthritis (OA) over 4 years.
METHODS: This study examined data from the Osteoarthritis Initiative (OAI), which included 4088 hips from 2057 participants. Bisphosphonate users were identified as those who reported usage at least three times, including at baseline and during the subsequent 1, 2, 3, and 4-year follow-up visits. Non-users were participants who did not use bisphosphonates in the 5 years preceding the baseline and at subsequent follow-up visits. Generalized estimating equations were performed to assess the association between bisphosphonate use and outcomes related to radiographic changes and pain in hip OA over a 4-year follow-up.
RESULTS: The analysis revealed no statistically significant difference between bisphosphonate users and non-users concerning outcomes related to radiographic changes and pain in hip OA over 4 years. Specifically, the odds ratios for the incidence and transition of radiographic hip OA were 0.55 (95% Confidence Interval [CI]: 0.26 to 1.17) and 0.78 (95% CI: 0.47 to 1.28), respectively. Furthermore, the odds ratios for the development and resolution of frequent hip pain were 1.04 (95% CI: 0.76 to 1.42) and 0.99 (95% CI: 0.72 to 1.36), respectively.
CONCLUSIONS: The findings from this longitudinal study do not suggest an association between bisphosphonate use and the prevention, slowing, or delay of development and transition of radiographic changes or pain in hip OA over a 4-year follow-up.
METHODS: This study examined data from the Osteoarthritis Initiative (OAI), which included 4088 hips from 2057 participants. Bisphosphonate users were identified as those who reported usage at least three times, including at baseline and during the subsequent 1, 2, 3, and 4-year follow-up visits. Non-users were participants who did not use bisphosphonates in the 5 years preceding the baseline and at subsequent follow-up visits. Generalized estimating equations were performed to assess the association between bisphosphonate use and outcomes related to radiographic changes and pain in hip OA over a 4-year follow-up.
RESULTS: The analysis revealed no statistically significant difference between bisphosphonate users and non-users concerning outcomes related to radiographic changes and pain in hip OA over 4 years. Specifically, the odds ratios for the incidence and transition of radiographic hip OA were 0.55 (95% Confidence Interval [CI]: 0.26 to 1.17) and 0.78 (95% CI: 0.47 to 1.28), respectively. Furthermore, the odds ratios for the development and resolution of frequent hip pain were 1.04 (95% CI: 0.76 to 1.42) and 0.99 (95% CI: 0.72 to 1.36), respectively.
CONCLUSIONS: The findings from this longitudinal study do not suggest an association between bisphosphonate use and the prevention, slowing, or delay of development and transition of radiographic changes or pain in hip OA over a 4-year follow-up.
摘要：
目的：本研究旨在探讨双膦酸盐与髋关节骨性关节炎（OA）4年的影像学改变和疼痛相关结局的关系。
方法：这项研究检查了骨关节炎倡议（OAI）的数据，其中包括2057名参与者中的4088名臀部。双膦酸盐使用者被确定为报告使用至少三次的人，包括基线和随后的1,2,3和4年随访.非使用者是在基线前5年和随后的随访中不使用双膦酸盐的参与者。进行了广义估计方程，以评估双膦酸盐使用与影像学改变和髋关节OA疼痛相关的结果之间的关联。
结果：分析显示，双膦酸盐使用者和非使用者在4年中与髋部OA的影像学改变和疼痛相关的结果无统计学差异。具体来说,影像学髋关节OA发生率和转变的比值比分别为0.55(95%置信区间[CI]:0.26至1.17)和0.78(95%CI:0.47至1.28),分别。此外，频繁髋部疼痛发展和消退的比值比分别为1.04(95%CI:0.76~1.42)和0.99(95%CI:0.72~1.36),分别。
结论：这项纵向研究的发现并不表明双膦酸盐的使用与预防之间存在关联，减速,在4年的随访中，或延迟影像学改变或髋关节OA疼痛的发展和过渡。
方法：这项研究检查了骨关节炎倡议（OAI）的数据，其中包括2057名参与者中的4088名臀部。双膦酸盐使用者被确定为报告使用至少三次的人，包括基线和随后的1,2,3和4年随访.非使用者是在基线前5年和随后的随访中不使用双膦酸盐的参与者。进行了广义估计方程，以评估双膦酸盐使用与影像学改变和髋关节OA疼痛相关的结果之间的关联。
结果：分析显示，双膦酸盐使用者和非使用者在4年中与髋部OA的影像学改变和疼痛相关的结果无统计学差异。具体来说,影像学髋关节OA发生率和转变的比值比分别为0.55(95%置信区间[CI]:0.26至1.17)和0.78(95%CI:0.47至1.28),分别。此外，频繁髋部疼痛发展和消退的比值比分别为1.04(95%CI:0.76~1.42)和0.99(95%CI:0.72~1.36),分别。
结论：这项纵向研究的发现并不表明双膦酸盐的使用与预防之间存在关联，减速,在4年的随访中，或延迟影像学改变或髋关节OA疼痛的发展和过渡。
